Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Top Page
Curis
(NASDAQ:CRIS)
48Neutral
Positive Factors
Clinical Trial Results
Curis reported 10 objective responses out of 19 response-evaluable patients: six patients with complete remission, two patients with CR with either a complete remission with incomplete hematological recovery or a partial hematologic recovery, and two patients with morphologic leukemia free state.
Financial Performance
Curis reported revenue and EPS that were better than the estimates.
Negative Factors
Price Target Adjustment
The price target is being lowered to $20 from $26 due to dilution from the offering.
Curis (CRIS) vs. S&P 500 (SPY)
Market Cap
$22.52M
Dividend YieldN/A
Average Volume (3M)29.53K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue Growth0.44%
EPS Growth16.44%
CountryUS
Employees49
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.81
Shares Outstanding8,466,957
10 Day Avg. Volume35,152
30 Day Avg. Volume29,531
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.20
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.00Price Target Upside660.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Curis Business Overview & Revenue Model
Company DescriptionCuris, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
How the Company Makes MoneyCuris makes money primarily through the development and licensing of its proprietary drug candidates. The company generates revenue by entering into strategic collaborations and licensing agreements with larger pharmaceutical partners who support the clinical development and commercialization of its therapies. This includes milestone payments and royalties based on the successful advancement and sales of its drug candidates. Additionally, Curis may receive research and development funding from these partnerships, which also contribute to its earnings. The company's financial performance is heavily influenced by the progress of its clinical trials, regulatory approvals, and market acceptance of its therapeutic products.
Curis Financial Statement Overview
Summary
Curis faces significant financial challenges, characterized by persistent losses and negative equity. Despite a strong gross profit margin, the company's profitability is hindered by high operational costs and leverage issues, posing risks to financial stability. Cash flow management needs improvement to enhance liquidity and sustainability.Income Statement
The company's income statement reflects significant challenges with persistent negative EBIT and net income over recent years. The gross profit margin remains high at approximately 93.6% for TTM, indicating efficient cost management. However, the negative net profit margin of -444% for TTM highlights ongoing operational inefficiencies and substantial losses. Revenue growth over the period has been stagnant, showing a slight increase of 2.35% from the previous year to TTM. Overall, profitability remains a critical concern.42
Neutral
Balance Sheet
Curis exhibits a highly leveraged balance sheet with negative stockholders' equity in the TTM period, indicating potential financial instability. The debt-to-equity ratio is not calculable due to negative equity, suggesting high financial risk. The equity ratio is negative, which reflects the challenges in sustaining financial health. The company needs to address its liabilities to improve financial stability.30
Negative
Cash Flow
The cash flow statement shows a positive shift in investing cash flow for TTM, but operating cash flow remains negative, putting pressure on liquidity. The free cash flow growth rate is negative compared to prior periods, indicating cash constraints. The operating cash flow to net income ratio is positive, suggesting some alignment between operational activities and accounting earnings despite being negative.55
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 10.26M | 10.02M | 10.16M | 10.65M | 10.84M | 10.00M | Gross Profit |
| 9.60M | 9.81M | 9.90M | 10.12M | 10.30M | 9.50M | EBIT |
| -47.75M | -48.33M | -53.02M | -42.06M | -24.90M | -24.36M | EBITDA |
| -46.54M | -45.14M | -50.51M | -39.98M | -24.67M | -27.17M | Net Income Common Stockholders |
| -45.55M | -47.41M | -60.32M | -50.64M | -34.88M | -36.80M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 24.27M | 56.33M | 85.62M | 139.85M | 183.06M | 20.54M | Total Assets |
| 37.37M | 77.28M | 108.85M | 162.30M | 204.36M | 35.11M | Total Debt |
| 35.48M | 2.79M | 6.74M | 5.04M | 7.66M | 166.00K | Net Debt |
| 11.85M | -23.89M | -12.92M | -34.97M | -121.95M | -15.26M | Total Liabilities |
| 41.86M | 57.61M | 62.30M | 71.59M | 73.69M | 69.02M | Stockholders Equity |
| -4.50M | 19.67M | 46.55M | 90.71M | 130.67M | -33.91M |
| Cash Flow | Free Cash Flow | ||||
| -40.49M | -38.43M | -54.75M | -37.62M | -26.42M | -26.25M | Operating Cash Flow |
| -40.49M | -38.43M | -54.34M | -37.62M | -25.74M | -26.20M | Investing Cash Flow |
| 44.39M | 37.79M | 33.02M | -47.90M | -49.05M | -4.46M | Financing Cash Flow |
| -7.51M | 7.58M | 867.00K | -4.17M | 188.81M | 23.27M |
Curis Technical Analysis
Negative
2.63
Price Trends
3.23
Negative
3.70
Negative
5.06
Negative
Market Momentum
-0.15
Positive
29.22
Positive
8.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 2.63 is below the 20-day moving average (MA) of 3.00, below the 50-day MA of 3.23, and below the 200-day MA of 5.06, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 29.22 is Positive, neither overbought nor oversold. The STOCH value of 8.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.
Curis Risk Analysis
Curis disclosed 61 risk factors in its most recent earnings report. Curis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Curis Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.61B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $41.63M | ― | 60.38% | ― | 16.15% | 59.81% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $22.52M | ― | -436.16% | ― | 0.44% | 16.44% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
41 Neutral | $62.62M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
CRIS
Curis
2.63
-7.61
-74.32%
KPTI
Karyopharm Therapeutics
7.53
-13.77
-64.65%
FGEN
FibroGen
0.46
-1.54
-77.00%
BPMC
Blueprint Medicines
90.50
-0.10
-0.11%
ADAP
Adaptimmune Therapeutics
0.46
-1.13
-71.07%
Curis Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: -33.08% | Next Earnings Date: Mar 18, 2025
Earnings Call Sentiment Positive
The earnings call highlights encouraging clinical trial results and effective cost management, as well as successful fundraising efforts. However, the ongoing net loss and enrollment challenges in the triplet study indicate areas of concern. Overall, the positive aspects of the clinical progress and financial management slightly outweigh the negatives.Highlights
Encouraging Results in TakeAim Lymphoma Study
The TakeAim Lymphoma study showed promising results with 10 evaluable patients, where there were 3 complete responses, 1 unconfirmed complete response, and 2 partial responses. The duration of response for 3 of the 4 patients with complete or unconfirmed complete responses was greater than 6 months.
Positive Progress in TakeAim Leukemia Study
In the TakeAim Leukemia study, 6 out of 11 evaluable patients with FLT3 mutation achieved an objective response, including 3 complete responses. Notably, 3 out of the 11 patients were naive to treatment with a FLT3 inhibitor, and all achieved an objective response.
Reduction in Net Loss and Expenses
Curis reported a net loss of $10.1 million for Q3 2024, a reduction from $12.2 million in Q3 2023. Research and development expenses decreased to $9.7 million from $10.4 million in the same period last year. General and administrative expenses also decreased to $3.8 million from $4.8 million.
Successful Fundraising
Curis completed a registered direct offering and private placement of unregistered warrants with net proceeds of approximately $10.8 million, bringing cash and cash equivalents to $31.6 million.
Lowlights
Ongoing Net Loss
Despite the reduction, Curis still reported a net loss of $10.1 million for Q3 2024 and $33.8 million for the first nine months of 2024.
Enrollment Challenges in Triplet Study
The company is facing challenges in enrolling patients for the triplet study with emavusertib, azacitidine, and venetoclax due to the specific patient criteria required for participation.
Company Guidance
During the Curis Third Quarter 2024 Earnings Call, the company provided guidance on its ongoing clinical trials and financial performance. Curis reported a net loss of $10.1 million or $1.70 per share for the third quarter of 2024, a decrease from the $12.2 million or $2.13 per share loss in the same period of 2023. The company highlighted its TakeAim Lymphoma study, which showed promising results with emavusertib and ibrutinib, reporting three complete responses and two partial responses among ten evaluable patients. The TakeAim Leukemia study also yielded positive results, with six of eleven evaluable patients achieving an objective response. Financially, research and development expenses decreased to $9.7 million, and general and administrative expenses reduced to $3.8 million, both compared to the same quarter of the previous year. Following a recent funding round, Curis's cash and cash equivalents stood at $31.6 million, expected to support operations into mid-2025. The company is actively engaging with regulatory authorities to define a path to approval for its treatments.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.